Clinical studies have shown that SGLT2 inhibitors can reduce the risk of diabetic cardiomyopathy (DCM) and chronic kidney disease (CKD) development in patients with and without diabetes [10,11,12]. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.